chrisvoncsefalvay/vaers-outcomes huggingface dataset:
INCOMPLETE DOSE ADMINISTERED; NEEDLE FAILURE; This spontaneous report received from a pharmacist . The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) 0.1 ml, administered on 11-MAY-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 11-MAY-2021, the subject experienced incomplete dose administered. On 11-MAY-2021, the subject experienced needle failure. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the incomplete dose administered and needle failure was not reported. This report was non-serious.
Uneasiness; tingling; tachycardia; Some abdominal queasiness; This is a spontaneous report from a contactable Physician (Patient). A 48-year-old non-pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot/batch number: EK9231), via an unspecified route of administration on 07Jan2021 13:15 at single dose in Left arm for COVID-19 immunization. Medical history included hypothyroidism, breast cancer and severe local/regional reaction to bee sting. The patient previously took tamoxifen for breast cancer (9-10 years before 10Jan2021). There were no known allergies. Concomitant medications which the patient received within 2 weeks of vaccination included levothyroxine, tamoxifen. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19. The patient experienced uneasiness, tingling followed by tachycardia within couple of minutes, some abdominal queasiness on 07Jan2021 13:15. Heart rate (HR) was 156. Seemed to subside over a period of 30 minutes. However slow waves of similar episodes occurred throughout the rest of the day, predominantly tachycardia and Gastrointestinal tract. Next day symptoms recurred and sustained a little longer. Sought evaluation. In Emergency department (ED), Labs unremarkable. One episode in ED with HR 151. Blood pressure (BP) maintained. Electrocardiogram (EKG) showed sinus tachycardia. Treated with steroids and Benadryl. On pulse dose steroids and Benadryl with overall improvement. The events resulted in Emergency room/department or urgent care. Treatments Solumedrol and Benadryl were received for the reported events. The outcome of the events was Recovering. This case reported as non-serious.
This spontaneous report was received from a consumer's father, and refers to a 4 year old female patient. The patients pertinent medical history included an urinary tract infection, for which the patient had "finished antibiotics (unspecified) 5-6 days prior to vaccination." The patient had none concomitant, drugs reactions or allergies. On 26-FEB-2018, the patient was vaccinated with her second dose of Oka/Merck VARIVAX for prevention from varicella (route reported as "injection") (anatomical location, lot #, and expiration date were not reported). On the same day, immediately after being administered the second dose of the Oka/Merck VARIVAX, the patient experienced a reaction at the injection site. Also, the patient experienced a rash the size of a golf ball at the injection site. The patient was monitored in the office for an extra half hour after being administered Oka/Merck VARIVAX. The office drew a circle around the rash. The physician's office was been calling the patient's father daily to check on the patient. The reporter stated that the patient is "physically fine," it's just the injection site reaction." The outcome of injection site reaction and injection site rash was reported as not recovered/not resolved. No treatment was given for the adverse events. The relatedness between the events and the varicella Oka/Merck VARIVAX was not reported.
Information has been received from a nurse concerning a female patient who "previously" on an unspecified date was vaccinated with a dose of RECOMBIVAX HB (Lot # not provided). On approximately 21-OCT-2010 "the patient is now found to have negative antibody titers". The patient sought unknown medical attention. Diagnostic laboratory test Hep B antibody testing performed. The patient's negative antibody titers persisted. Additional information has been requested.
Full body hives/urticaria; itching; hot to touch; Full body rashes; low grade fever of 98-102 deg F; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (Full body hives/urticaria), PRURITUS (itching), FEELING HOT (hot to touch), RASH (Full body rashes) and PYREXIA (low grade fever of 98-102 deg F) in a 38-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 032L20A) for COVID-19 vaccination.     Concomitant products included PREDNISONE, CETIRIZINE and RANITIDINE HYDROCHLORIDE (ZANTAC) for an unknown indication.    On 09-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-Feb-2021, the patient experienced URTICARIA (Full body hives/urticaria), PRURITUS (itching), FEELING HOT (hot to touch), RASH (Full body rashes) and PYREXIA (low grade fever of 98-102 deg F). At the time of the report, URTICARIA (Full body hives/urticaria), PRURITUS (itching), FEELING HOT (hot to touch), RASH (Full body rashes) and PYREXIA (low grade fever of 98-102 deg F) outcome was unknown.            No treatment medication information was provided   Most recent FOLLOW-UP information incorporated above includes: On 06-Jul-2021: Follow-up information received on 06-jul-2021 contains non-significant information- added reporter's email and address
Rough night.  Fever, chills, headache, nausea.  Started at about 11pm.  Took some Aleve before bed then at 3 am too Tylenol and that helped more. Got up at 7 and came to work. Took more tylenol this AM, so other than a mild headache, doing fine.
Started feeling bad/as sick as he was he could not get the second dose; Pain in the body; Could not sleep at night; hands "fell asleep"; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (Started feeling bad/as sick as he was he could not get the second dose), PAIN (Pain in the body), INSOMNIA (Could not sleep at night) and PARAESTHESIA (hands "fell asleep") in a 51-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 045A21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history).    On 17-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Mar-2021, the patient experienced VACCINATION COMPLICATION (Started feeling bad/as sick as he was he could not get the second dose), PAIN (Pain in the body), INSOMNIA (Could not sleep at night) and PARAESTHESIA (hands "fell asleep"). At the time of the report, VACCINATION COMPLICATION (Started feeling bad/as sick as he was he could not get the second dose), PAIN (Pain in the body), INSOMNIA (Could not sleep at night) and PARAESTHESIA (hands "fell asleep") had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.  On 20 Mar 2021, the patient started felling bad and was having pain in the body.  He went to the emergency room as he could not sleep at night and also his hands "fell asleep."  The patient was treated with meloxicam and referred to a specialist.  The patient said these symptoms were ongoing and getting worse over time.  Per the patient, his doctor said "as sick as he was he could not get the second dose".  The patient then asked if he could get the second dose.  Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Pain for 2 days. Oblong area around shot site 3" wide and 5-6 inches long, red raised and tender to touch with arm swelling. Hx 3-28-19 no raised red welt. Swelling decreased.
Dizziness, nausea, vomiting, muscular pain, digestive pain, migraine headaches. Every day, all day since the shot.
2 trips to ER - itching, tightness in throat & chest & sides of ribs, disorientation, some swelling of face & tongue, general malaise, throat red but not sore
pt recvd vax 26MAR94 & 9APR94 pt exp aches in the arms, knees & feet which persisted x 1 wk; @ the time of report pt continued to exp soreness in all of the toes; No further details were provided;
Pt recv vax on 9/23/98; afterwards pt exp nausea, lightheaded, tight chest, dizzy, skin warm &dry.  Pt seen by M.D.
Pt c/o chest tightening, scratchy throat BP 147/100, pulse 95, o2 100% RA. 10 mg Zyrtec given, 10 mins later p/o feeling flushed and needed to lay down. Pt transferred to gurney via WC. 30 mins later symptoms still present, accompanied by a piercing frontal HA, pain 8 out of 10.  BP 188/111, pulse 90, o2 98 %. Pt then c/o of throat closing, she felt that she couldn't breathe, Dr ordered Epi pen to be given, symptoms resolved and pt transferred to ED for further observation. Bp 178/109, pulse 100. o2 99%, upon being transferred.
abdomen pain; metrorrhagia; This is a spontaneous report from a contactable consumer (patient). This 34-year-old female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) Lot number EW0165, on 01May2021 at single dose in left arm (at the age of 34-year-old) for COVID-19 immunization.  Medical history was none. The patient had no known allergies. The patient was not diagnosed with COVID-19 prior to vaccination. The patient had not been tested for COVID-19 since the vaccination. Concomitant medication was none. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not receive any other medications within 2 weeks of vaccination. The patient previously received first dose of BNT162B2, Lot number EN6207, on 10Apr2021 11:00 in left arm forCovid-19 Immunization. After getting 2nd dose, the patient started to have metrorrhagia starting the 2 days after (03May2021). It lasted for 2 weeks. She never had a metrorrhagia in her entire life. She called hospital to report side effects, but they said she needed to see her doctor regarding this. She went to gynecology to see what's going on, and he said there wasn't any study regarding women's metrorrhagia side effect, but he had seen a lot of women suffering similar issue after getting vaccine, such as re-starting period after menopause. It's been almost 4 months since she got vaccinated, and she still had abdomen pain sometimes. Her biggest concern was that it would affect her body for not getting pregnant. They had been trying to get pregnant since 3 months and it's not happening. She was really worried. She was hearing similar side effects from a lot of people nowadays. No treatment was received. The outcome of the events was not resolved. The event metrorrhagia was serious with life-threatening.
Patient experienced general malaise for a day then threw up several times the night after.  No fever or chills.
Started with chills; Tiredness; 100 degree fever; Headache; Faster heartbeat; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: er 8737), via an unspecified route of administration in the left arm on 08Apr2021 at 17:00 (at the age of 50-years-old), as a single dose for COVID-19 immunisation. Medical history included extra heartbeat, COVID-19 and sulfonamide allergy.  Concomitant medications included Alive multi-vit, 2 calcium pills (MANUFACTURER UNKNOWN), cetirizine hydrochloride (ZYRTEC) and biotin (MANUFACTURER UNKNOWN); all from an unknown date for unspecified indications. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 09Apr2021 at 15:00, next afternoon the patient experienced started with chills, tiredness and then 100-degree fever with headache, faster heartbeat. The patient took an ibuprofen & slept most of the afternoon/evening and rest of night, and felt better next day. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. On 09Apr2021 at 15:00, the patient underwent lab test and procedure which included body temperature and result was shown as 100-degree. The clinical outcome of the events chills, tiredness and then 100-degree fever with headache, faster heartbeat were recovering at the time of reporting.   No follow-up attempts are needed. No further information is expected.
Patient received higher dose of vaccine due to vaccine not being diluted correctly.  Patient was monitored.  No reaction noted.
Local swelling, warmth, redness 2 hr after injection with a few scattered hives, L cheek and 2 near injection site.
Metallic taste in her mouth; Heart burns; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A female patient received bnt162b2 (BNT162B2), administration date Mar2022 (Batch/Lot number: unknown) as dose 4 (booster), single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary immunization series complete; unknown manufacturer), for Covid-19 immunization; Bnt162b2 (1st booster dose of Pfizer Covid 19 vaccine.), for Covid-19 immunization. The following information was reported: DYSGEUSIA (non-serious) with onset Mar2022, outcome "unknown", described as "Metallic taste in her mouth"; DYSPEPSIA (non-serious) with onset Mar2022, outcome "unknown", described as "Heart burns".  The lot number for bnt162b2 was not provided and will be requested during follow up.
within a minute of the shot (2nd of the series) patient reported graying/reddening of vision and weakness/fainting - sat on ground - drank water - ate cookies - over 10 minutes patient felt better - EMT came in and checked him out - bp at that time 108/60 pulse 60 - blood sugar 66 - after 10 minutes tried to stand - felt weak and dizzy again - vision disturbed again - bp 110/70 - EMT suggested hospital - patient went to hospital
Information has been received from a nurse concerning a 22 year old female with no known drug allergies and no pertinent medical history, who on 18-JUL-2008 was vaccinated with the first dose of GARDASIL vaccine (yeast) (lot # 660557/0072X) 0.5 mL, IM into her right deltoid. There was no concomitant therapy. The patient was sitting on the exam table and after GARDASIL vaccine (yeast) was administered, she fainted and fell forward onto the floor and broke her nose. She was taken to the emergency room (ER) but was admitted. The patient told the nurse she is not afraid of needles, injections or blood being drawn, but never had an experience like this. At the time of reporting, the patient was recovering. Additional information has been requested.
I came down with CIDP, Guillain-Barre within 60 days of flu shot.
22 y/o male ADSM is referred from the Smallpox study with complaint of a single episode of chest pain on yesterday evening.  Possible adverse reaction to Smallpox vaccine.  Symptoms: Chest Pain, Dyspnea (shortness of breath).
12/16 had pain (L) upper arm shortly after getting shot 12/17/12 - (L) neck pain, (L) upper arm pain radiating to distal forearm, (L) thigh pain - tenderness of (L) upper arm and (L) thigh. 12/18 - neck pain resolved but still had (L) upper arm and (L) thigh pain - ibuprofen 400 q 6 hours, see if no improvement.
PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE UNSTABLE ANGINA ANGINA, UNSPECIFIED 12/8/2022 -- RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Vaccine was stored in refrigerator on 04-Jun-2022 and administered vaccine on 18-Jul-2022; No adverse event; Patient administered the vaccine after the 30 day by used; This spontaneous case was reported by a physician assistant and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient administered the vaccine after the 30 day by used), PRODUCT STORAGE ERROR (Vaccine was stored in refrigerator on 04-Jun-2022 and administered vaccine on 18-Jul-2022) and NO ADVERSE EVENT (No adverse event) in a 47-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 058A22-2A) for COVID-19 prophylaxis.     No Medical History information was reported.   On 18-Jul-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 18-Jul-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient administered the vaccine after the 30 day by used). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine was stored in refrigerator on 04-Jun-2022 and administered vaccine on 18-Jul-2022) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient administered the vaccine after the 30 day by used), PRODUCT STORAGE ERROR (Vaccine was stored in refrigerator on 04-Jun-2022 and administered vaccine on 18-Jul-2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Patient administered the vaccine after the 30 day by used) and PRODUCT STORAGE ERROR (Vaccine was stored in refrigerator on 04-Jun-2022 and administered vaccine on 18-Jul-2022).    No concomitant product use was reported.  It was reported that, patient received half dose. The vial did not undergo any temperature excursions.  The vial was initially stored in the refrigerator on 4 Jun 2022  No treatment information was provided.
The Medical Assistant reported a temperature excursion for refrigerated vaccine.; This spontaneous report was received from a Medical Assistant referring to a patient of unknown age and gender. The patient's medical history, concurrent conditions, concomitant medications, and historical drugs were not reported.  On 23-MAR-2021, the patient was vaccinated with an improperly stored dose of hepatitis rotavirus vaccine, live, oral, pentavalent(ROTATEQ) dose 1 (units not provided), per oral route (strength, dose #, frequency, and anatomical location were unknown) with lot # 1691301 and expiration date 12-DEC-2021 for prophylaxis.The patient was asyntomatic.  The administered dose of vaccine experience the temperature excursion on one of these dates, 22-FEB-2021, 25-FEB-2021, 02-MAR-2021, 05-MAR-2021, 09-MAR-2021, 15-MAR-2021, and 19-MAR-2021, of 35.6, 35.7, or 35.9  degrees Fahrenheit for 15 minutes; on 17-MAR-2021, the temperature excursion of 35.7 degrees Fahrenheit for 30 minutes;  on 18-MAR-2021 and 28-MAR-2021, of 35.2 and 35.9 degrees Fahrenheit for 45 minutes; on 25-MAR-2021, of 35.2 degrees Fahrenheit for 4 hours and 15 minutes; on 26-MAR-2021, of 35.4 degrees Fahrenheit for 2 hours and 45 minutes; or on 27-MAR-2021, of 35.9 degrees Fahrenheit 1 hour and 30 minutes.  There was no digital data logger involved, and no previous temperature excursion. The vaccine program did an audit, and they were unaware of the excursions.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2105USA002850: US-009507513-2105USA003496: US-009507513-2105USA003497: US-009507513-2105USA003498: US-009507513-2105USA003499: US-009507513-2105USA003500: US-009507513-2105USA003501: US-009507513-2105USA003502: US-009507513-2105USA003503: US-009507513-2105USA003504: US-009507513-2105USA003505: US-009507513-2105USA003506: US-009507513-2105USA003507: US-009507513-2105USA003508: US-009507513-2105USA003509: US-009507513-2105USA003510: US-009507513-2105USA003511: US-009507513-2105USA003512: US-009507513-2105USA003513: US-009507513-2105USA003514: US-009507513-2105USA003515: US-009507513-2105USA003516: US-009507513-2105USA003517: US-009507513-2105USA003518: US-009507513-2105USA003519: US-009507513-2105USA003520: US-009507513-2105USA003521: US-009507513-2105USA003522: US-009507513-2105USA003523: US-009507513-2105USA003524: US-009507513-2105USA003526: US-009507513-2105USA003527: US-009507513-2105USA003528: US-009507513-2105USA003529: US-009507513-2105USA003530: US-009507513-2105USA003531: US-009507513-2105USA003532: US-009507513-2105USA003533: US-009507513-2105USA003534: US-009507513-2105USA003535: US-009507513-2105USA003536: US-009507513-2105USA003537: US-009507513-2105USA003538: US-009507513-2105USA003539: US-009507513-2105USA003540: US-009507513-2105USA003541: US-009507513-2105USA003542: US-009507513-2105USA003543:
Information has been received from a doctor of pharmacist concerning a 17 year old female patient with no pertinent medical history and no known drug allergies/drug reactions, who completed her GARDASIL vaccine series "sometime" last year. Concomitant therapy included hormonal contraceptives (unspecified) and vitamins (unspecified). It was reported that about a month after completion of the series the patient began to develop "stabbing left hemisphere head pain and numbness to the left arm and leg. It was reported that the patient has continued to have biweekly "attacks" since the beginning of symptoms. At the time of reporting the patient had a blood work, head computed axial tomography and an magnetic resonance imaging of head done. All results were negative. At the time of the report the patient had not recovered. The patient sought medical attention with the neurologist. Additional information has been requested. Follow-up information received from the physician's office who reported that the 16-year-old female patient (previously reported at 17 years old) was experiencing headaches prior to receving the third dose of GARDASIL given in October 2008 (previously re ported as 2009, month unknown). Onset date of headaches and hypaesthesia was reported as November 2008 dose. The patient was seen by neurologist in late December/ early January and was diagnosed with migranines. The patient was not hospitalized and is currently doing fine. No further information is available.   3/16/09 Received Neuro medical records of 1/8-2/18/2009. FINAL DX: probable basilar migraine Records reveal patient experienced four spells of unconsciousness, pallor, slurred speech over several weeks preceded by blurred vision & seeing spots.  Has had frequent dizziness, right parietal pain, contralateral arm & leg tingling.  Referred for MRI & tx w/meds.  RTC 2/18 w/good response to meds.
After about two weeks of the second dose Covid-19 vaccine, I feel more and more difficult in breath when I was running or doing sport excises. My chest felt painful when doing the excises. I normally run in 5.8 miles/hour. In two weeks of fully vacationed, I can only run in 3.8 miles/hour.